BiomX Inc.
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About BiomX Inc.
BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).
/ 
Others were interested in
See all stocksFrequently asked questions
To buy BiomX Inc. stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for BiomX Inc. by name or ticker, choose the number of shares, and place your order.
The ticker symbol for BiomX Inc. is PHGE:xase. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
BiomX Inc. has its primary listing on NYSE American. You can trade BiomX Inc. with a Saxo account, alongside thousands of other stocks worldwide.
Yes, BiomX Inc. is available to trade on SaxoInvestor and SaxoTraderGO. You can buy shares directly and include BiomX Inc. as part of a broader investment portfolio. Explore our SaxoInvestor platform.
Learn more about investing and trading at Saxo’s educational content hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures— so you can make more informed decisions when considering shares like BiomX Inc..